Novel investigational biologics for the treatment of cancer cachexia
- PMID: 24707881
- DOI: 10.1517/14712598.2014.907788
Novel investigational biologics for the treatment of cancer cachexia
Abstract
Introduction: Cancer cachexia is a complex multifactorial syndrome characterized by ongoing, irreversible skeletal muscle loss, leading to progressive functional impairment. Several investigational biologics targeting key inflammatory pathways and/or the myostatin/activin type II receptor pathway are in development.
Areas covered: Novel therapies include ALD518, MABp1, IP-1510, OHR/AVR118, bimagrumab and REGN1033 and are discussed. For each investigational therapy, the mechanism of action, preclinical data, cachexia definition, indication and clinical data are discussed.
Expert opinion: A critical look of the study protocols and two key challenges limiting the successful evaluation of these agents include: i) lack of a clinically meaningful cachexia definition; and ii) identification and treatment of cachexia in late stage. We describe our observations and clinical experience in an effort to redirect and promote successful strategies to evaluate these novel investigational biologics.
Keywords: cachexia; cancer; myostatin; skeletal muscle loss.
Similar articles
-
Peptide-2 from mouse myostatin precursor protein alleviates muscle wasting in cancer-associated cachexia.Cancer Sci. 2020 Aug;111(8):2954-2964. doi: 10.1111/cas.14520. Epub 2020 Jul 1. Cancer Sci. 2020. PMID: 32519375 Free PMC article.
-
Investigational drugs for the treatment of cancer cachexia: a focus on phase I and phase II clinical trials.Expert Opin Investig Drugs. 2019 Aug;28(8):733-740. doi: 10.1080/13543784.2019.1646727. Epub 2019 Jul 26. Expert Opin Investig Drugs. 2019. PMID: 31347405 Review.
-
Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):12448-12453. doi: 10.1073/pnas.1707925114. Epub 2017 Nov 6. Proc Natl Acad Sci U S A. 2017. PMID: 29109273 Free PMC article.
-
Molecular Pathways: Cachexia Signaling-A Targeted Approach to Cancer Treatment.Clin Cancer Res. 2016 Aug 15;22(16):3999-4004. doi: 10.1158/1078-0432.CCR-16-0495. Epub 2016 Jun 23. Clin Cancer Res. 2016. PMID: 27340276 Free PMC article. Review.
-
Phase II drugs that are currently in development for the treatment of cachexia.Expert Opin Investig Drugs. 2014 Dec;23(12):1655-69. doi: 10.1517/13543784.2014.942729. Epub 2014 Jul 24. Expert Opin Investig Drugs. 2014. PMID: 25056249 Review.
Cited by
-
Sex specificity of pancreatic cancer cachexia phenotypes, mechanisms, and treatment in mice and humans: role of Activin.J Cachexia Sarcopenia Muscle. 2022 Aug;13(4):2146-2161. doi: 10.1002/jcsm.12998. Epub 2022 May 5. J Cachexia Sarcopenia Muscle. 2022. PMID: 35510530 Free PMC article.
-
Nexrutine® preserves muscle mass similar to exercise in prostate cancer mouse model.Physiol Rep. 2019 Aug;7(16):e14217. doi: 10.14814/phy2.14217. Physiol Rep. 2019. PMID: 31456341 Free PMC article.
-
Biologics in Chronic Rhinosinusitis: An Update and Thoughts for Future Directions.Am J Rhinol Allergy. 2018 Sep;32(5):412-423. doi: 10.1177/1945892418787132. Epub 2018 Jul 19. Am J Rhinol Allergy. 2018. PMID: 30021447 Free PMC article. Review.
-
Cancer-induced muscle wasting: latest findings in prevention and treatment.Ther Adv Med Oncol. 2017 May;9(5):369-382. doi: 10.1177/1758834017698643. Epub 2017 Mar 8. Ther Adv Med Oncol. 2017. PMID: 28529552 Free PMC article. Review.
-
Mechanisms of metabolic dysfunction in cancer-associated cachexia.Genes Dev. 2016 Mar 1;30(5):489-501. doi: 10.1101/gad.276733.115. Genes Dev. 2016. PMID: 26944676 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
